Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT02526290 Completed - Dry Eye Syndromes Clinical Trials

Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator

Start date: August 31, 2015
Phase: N/A
Study type: Interventional

In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.

NCT ID: NCT02254265 Completed - Dry Eye Disease Clinical Trials

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).

NCT ID: NCT02188160 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Kauai
Start date: June 2014
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT02139033 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

Start date: May 2014
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.

NCT ID: NCT02121301 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

NCT ID: NCT02117687 Completed - Dry Eye Syndromes Clinical Trials

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

Start date: May 14, 2014
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

NCT ID: NCT02051023 Completed - Dry Eye Clinical Trials

Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)

FML
Start date: February 2014
Phase: Phase 3
Study type: Interventional

Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates the worsening of the disease after exposure to an adverse controlled environment.

NCT ID: NCT02040623 Completed - Clinical trials for Chronic Graft-versus-host Disease

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

DROPS-2
Start date: March 2014
Phase: Phase 2
Study type: Interventional

- To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. - To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.

NCT ID: NCT01977443 Completed - Clinical trials for Viral Conjunctivitis

Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

Start date: November 2013
Phase: Phase 2
Study type: Interventional

A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

NCT ID: NCT01900249 Completed - Clinical trials for Keratoconjunctivitis Sicca

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

DROPS
Start date: July 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.